Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.

Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D, Richards JD, Cervi P, Kinsey S, Goldstone AH.

Br J Haematol. 1992 Jun;81(2):197-202.

PMID:
1643017
2.

The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.

Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH.

Blood. 1993 Mar 1;81(5):1137-45.

3.

Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.

Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, Pantolony D, Keating A, Crump M.

Ann Oncol. 1997 Jul;8(7):675-80.

5.

Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.

Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.

Haematologica. 1999 Nov;84(11):1007-11.

6.

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.

Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM, Scott JG, Sutcliffe SB, Brandwein JM, Keating A.

J Clin Oncol. 1995 Feb;13(2):396-402.

PMID:
7844600
7.

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH.

J Clin Oncol. 1995 Mar;13(3):588-95.

PMID:
7884420
9.

Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.

Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A.

Bone Marrow Transplant. 1990 Feb;5(2):99-103.

PMID:
2310878
11.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV.

Lancet. 1993 Apr 24;341(8852):1051-4.

PMID:
8096958
12.

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.

Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D, et al.

J Clin Oncol. 1993 Apr;11(4):704-11.

PMID:
8478664
14.
15.

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

Martín A, Fernández-Jiménez MC, Caballero MD, Canales MA, Pérez-Simón JA, García de Bustos J, Vázquez L, Hernández-Navarro F, San Miguel JF.

Br J Haematol. 2001 Apr;113(1):161-71.

PMID:
11328296
16.

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.

Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R, et al.

J Clin Oncol. 1994 Mar;12(3):580-6.

PMID:
8120557
18.

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.

Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, et al.

J Clin Oncol. 1989 Feb;7(2):179-85.

PMID:
2644397
19.

[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].

Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.

Harefuah. 2000 Sep;139(5-6):174-9, 248, 247. Hebrew.

PMID:
11062945
20.

Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.

Gaspard MH, Maraninchi D, Stoppa AM, Gastaut JA, Michel G, Tubiana N, Blaise D, Novakovitch G, Rossi JF, Weiller PJ, et al.

Cancer Chemother Pharmacol. 1988;22(3):256-62.

PMID:
3044633
Items per page

Supplemental Content

Write to the Help Desk